<DOC>
	<DOCNO>NCT03101644</DOCNO>
	<brief_summary>This study ass characterize variability observe response darunavir therapy , antiretroviral medication use Human Immunodeficiency Virus ( HIV ) . More specifically , aim quantify variation drug 's blood concentration determine source variability , genetic non-genetic . In light information , current dosage guideline review .</brief_summary>
	<brief_title>Optimization Darunavir Therapy Dosage Recommendations</brief_title>
	<detailed_description>Data use create population pharmacokinetic model . Inter- intra-individual pharmacokinetic variability quantify link patient-specific covariates , genetic non-genetic nature . Pharmacokinetic-pharmacodynamic relationship establish , link drug exposure efficacy ( measure CD4 cell count viral load reduction ) toxicity ( measured frequency degree adverse event ) . Simulations conduct specific patient profile current dosage guideline review .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Capable give informed consent HIVpositive Routinely follow Cliniques universitaires SaintLuc Treated darunavir N/A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>